The latest news
-
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
Amylyx Pharmaceuticals, Inc. today announced that Health Canada has approved ALBRIOZA™, with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). This decision marks the first marketing approval for ALBRIOZA issued to Amylyx worldwide.
-
ETNA™ Device from Leading Digital Health & AI Company Innodem Neurosciences Receives FDA “Breakthrough” Designation for Multiple Sclerosis
Innodem Neurosciences, a leading provider of innovation and technology for the convergence of neurosciences, digital health, pharmaceutical and artificial intelligence, is proud to announce that its novel mobile eye tracking technology for people living with multiple sclerosis .
-
A novel collaboration from Brain Canada and the ALS Society of Canada brings decades of expertise to ALS Research
The Discovery Grant Program is designed to fuel innovation that will accelerate our understanding of ALS, identify pathways for future theraphies and optimize care to improve quality of life for people and families affected by this devasting disease.